Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GLAXF) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to 30.34%.

  • Gsk's EBITDA Margin rose 279800.0% to 30.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.41%, marking a year-over-year increase of 53900.0%. This contributed to the annual value of 12.82% for FY2024, which is 94200.0% down from last year.
  • Per Gsk's latest filing, its EBITDA Margin stood at 30.34% for Q3 2025, which was up 279800.0% from 25.33% recorded in Q2 2025.
  • Over the past 5 years, Gsk's EBITDA Margin peaked at 61.57% during Q4 2021, and registered a low of 2.36% during Q3 2024.
  • Over the past 5 years, Gsk's median EBITDA Margin value was 23.9% (recorded in 2022), while the average stood at 25.11%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -376800bps in 2022, then surged by 279800bps in 2025.
  • Quarter analysis of 5 years shows Gsk's EBITDA Margin stood at 61.57% in 2021, then plummeted by -61bps to 23.9% in 2022, then grew by 25bps to 29.89% in 2023, then crashed by -31bps to 20.57% in 2024, then soared by 48bps to 30.34% in 2025.
  • Its EBITDA Margin was 30.34% in Q3 2025, compared to 25.33% in Q2 2025 and 29.48% in Q1 2025.